创响生物与Ikena Oncology合并,融资7500万美元 ,OX40 单克隆抗体能否撑起未来?

市场资讯
25 Dec 2024

2024年12月23日(GLOBENEWSWIRE)——IkenaOncology,Inc.(纳斯达克股票代码:IKNA,“Ikena”)和InmageneBiopharmaceuticals(“Inmagene”、“创响生物”)宣布双方已达成最终合并协议。在此次合并中,Ikena已与DeepTrackCapital、ForesiteCapital、RTWInvestments等新投资者达成认购...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10